Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
402 pending office actions • 192 clients • 332 examiners • 112 art units • 0 of 402 (0%) have an AI response strategy ready
GOODWIN PROCTER LLP has a history in the Biotechnology & Pharmaceuticals technology area, having handled 12315 career applications. This volume of 12315 applications establishes the firm as a participant in this sector. Currently, the firm is managing a docket of 322 pending office actions, reflecting its large-scale operations.
The firm maintains a resolved allowance rate of 74.52 percent. This outcome is reached with an average of 3.51 office actions per allowance. This 3.51 average indicates a prosecution process that typically requires multiple rounds of interaction with the patent office to secure a grant in the Biotechnology & Pharmaceuticals field. The 74.52 percent allowance rate across 12315 career applications provides a benchmark for their success in this technical area.
With 322 pending office actions, the firm continues to be active in patent prosecution. The 12315 career applications provide a dataset for evaluating their long-term performance. Practitioners can use the 74.52 percent resolved allowance rate and the 3.51 average office actions per allowance to evaluate the firm's typical prosecution path and success rate for biotech and pharmaceutical patents.
Based on the USPTO statutory response window for each pending office action. 126 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 126 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 3 (1%) |
| §101 + other | 48 (12%) |
| §103 only | 83 (21%) |
| §102 only | 11 (3%) |
| §112 only | 24 (6%) |
| Double-patenting only | 19 (5%) |
| Double-patenting + other | 58 (14%) |
| Multi-statute (no §101) | 150 (37%) |
| No statute on record | 6 (1%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WANG, JING | 4 | 100.0% | +0.0% |
| GOLLAMUDI, NEERAJA | 4 | 72.7% | +39.9% |
| HASAN, KHALEDA B | 4 | 59.7% | +48.5% |
| GODDARD, LAURA B | 3 | 50.9% | +13.5% |
| SEITZ, ANTHONY JOSEPH | 3 | 67.9% | +27.3% |
| KALISZEWSKI, ALINA ROSE | 3 | 84.6% | +23.3% |
| SMALE, AVERY E | 3 | 73.8% | +19.8% |
| RYAN, DOUGLAS CHARLES | 3 | 39.2% | +47.6% |
| SWANSON, LEAH JENNINGS | 3 | 65.6% | +37.9% |
| BAHENA, CHRISTIE L. | 3 | 68.2% | +23.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568165 | VACUUM SYSTEM FOR A MASS SPECTROMETER | WANG, JING | 38d overdue |
| 17998012 | AN ATMOSPHERIC PRESSURE IONISATION SOURCE | KALISZEWSKI, ALINA ROSE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18612960 | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs | HUYNH, PHUONG N | 238d overdue |
| 18145772 | SARS-COV-2 SERUM ANTIBODY PROFILING | ZOU, NIANXIANG | 162d overdue |
| 17800958 | METHODS AND COMPOSITIONS FOR MODULATING ARGININE LEVELS IN IMMUNE CELLS | DHAR, MATASHA | 147d overdue |
| 17879923 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | JAVANMARD, SAHAR | 147d overdue |
| 17157043 | Dynamically Changing Promotions Displayed on a Mobile Device and Measuring The Benefit Thereof | OSMAN BILAL AHMED, AFAF | 147d overdue |
| 18085792 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | JAVANMARD, SAHAR | 142d overdue |
| 18042375 | NEBULIZER DEVICE OPTIMIZATION FOR IMPROVED AEROSOL PARAMETERS AND USES THEREOF | PINDERSKI, JACQUELINE M | 104d overdue |
| 17552935 | METHODS, MEDIUMS, AND SYSTEMS FOR BUILDING AND EXECUTING A CHROMATOGRAPHY WORKFLOW | GAVIN, KRISTIN ELIZABETH | 99d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016838 | METHOD FOR CONTROLLING A PROSTHESIS OR ORTHOSIS | BAHENA, CHRISTIE L. | 35d overdue |
| 18246783 | METHOD FOR CONTROLLING A PROSTHETIC FOOT | BAHENA, CHRISTIE L. | 28d overdue |
| 18042193 | A METHOD FOR THE ISOLATION OF DOUBLE-STRAND BREAKS | RYAN, DOUGLAS CHARLES | 3d overdue |
| 16859544 | FILLING ASSIST MECHANISMS AND KEYED INTERFACES FOR DRUG DELIVERY DEVICES | SWANSON, LEAH JENNINGS | 3d overdue |
| 18386647 | PROGRAMMATIC MEDICAMENT TITRATION WITH A MEDICAMENT DELIVERY DEVICE | SWANSON, LEAH JENNINGS | 14d |
| 16995527 | RATCHET DRIVE FOR ON BODY DELIVERY SYSTEM | SWANSON, LEAH JENNINGS | 14d |
| 18016827 | ORTHOPAEDIC JOINT DEVICE | BAHENA, CHRISTIE L. | 21d |
| 19569819 | TRISPECIFIC COMPOSITIONS COMPRISING IL-2, VEGF BINDING DOMAINS, AND PD-1 BINDING DOMAINS | GODDARD, LAURA B | — |
| Art Unit | Apps |
|---|---|
| 3783 | 39 |
| 2881 | 10 |
| 1618 | 9 |
| 1642 | 8 |
| 1635 | 8 |
| 1623 | 8 |
| 1625 | 7 |
| 1626 | 7 |
| 1636 | 7 |
| 3774 | 7 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19569819 | TRISPECIFIC COMPOSITIONS COMPRISING IL-2, VEGF BINDING DOMAINS, AND PD-1 BINDING DOMAINS | Bright Peak Therapeutics AG | GODDARD, LAURA B | 1642 | §103§112DP | Non-Final OA | — | Pending | Mar 17, 2026 |
| 19548526 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | University of Basel | PERREIRA, MELISSA JEAN | 1618 | §102§103DP | Non-Final OA | — | Pending | Feb 24, 2026 |
| 19545401 | FORMULATIONS OF VIMSELTINIB | Deciphera Pharmaceuticals, LLC | PAK, JOHN D | 1699 | §103§112DP | Final Rejection | — | Pending | Feb 20, 2026 |
| 19544595 | FORMULATIONS OF VIMSELTINIB | Deciphera Pharmaceuticals, LLC | LEE, SIN J | 1613 | §102§103§112 | Final Rejection | — | Pending | Feb 19, 2026 |
| 19434846 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RADIATION INDUCED TOXICITY | Zydus Lifesciences Limited | OH, TAYLOR V | 1625 | §103 | Final Rejection | — | Pending | Dec 29, 2025 |
| 19432924 | AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN | Kashiv Biosciences, LLC | REGLAS, GEORGIANA C | 1651 | §102 | Final Rejection | — | Pending | Dec 24, 2025 |
| 19432904 | AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN | Kashiv Biosciences, LLC | MCDERMOTT, JEANNIE | 1776 | §103§112Other | Non-Final OA | — | Pending | Dec 24, 2025 |
| 19397828 | TREATMENT OF DIABETIC RETINOPATHY USING ENDOTHELIN RECEPTOR ANTAGONISTS | Perfuse Therapeutics, Inc. | BASQUILL, SEAN M | 1614 | §103 | Final Rejection | — | Pending | Nov 21, 2025 |
| 19353469 | COMPOSITIONS, DEVICES, AND METHODS RELATING TO USE OF AN AMNIOTIC MEMBRANE FETAL TISSUE PRODUCT | BIOTISSUE HOLDINGS INC. | WESTON, ALYSSA G | 1633 | §102§103 | Final Rejection | — | Pending | Oct 08, 2025 |
| 19348728 | ORAL MUCOSAL FORMULATIONS OF ASPIRIN | Aspire Biopharma Holdings, Inc. | SONG, JIANFENG | 1613 | §103DP | Final Rejection | — | Pending | Oct 02, 2025 |
| 19344208 | CRYOGENIC COOLING SYSTEM WITH A RESONANT EXPANDER | R7 Instruments, Inc. | LARGI, MATTHEW THOMAS | 3746 | §102§112 | Final Rejection | — | Pending | Sep 29, 2025 |
| 19338730 | TRANSDERMAL DEXMEDETOMIDINE FOR TREATING AGITATION | Teikoku Pharma Usa, Inc. | HAVLIN, ROBERT H | 1626 | §103DP | Final Rejection | — | Pending | Sep 24, 2025 |
| 19339016 | TIERED TESTING FOR HIGH RISK POPULATIONS | Harbinger Health, Inc. | SMITH, EMILIE ALINE | 1686 | §101§112DP | Non-Final OA | — | Pending | Sep 24, 2025 |
| 19288411 | MULTI-TIERED TESTING FOR TRACKING DISEASE HETEROGENEITY | Flagship Pioneering Innovations Vi, LLC | SKIBINSKY, ANNA | 1635 | §101§103 | Non-Final OA | 50d overdue | Pending | Aug 01, 2025 |
| 19284259 | SYSTEMS AND METHODS FOR DENTAL TREATMENT WITH EKF | T33 Dental, Inc. | GONZALEZ, LEI NMN | 3783 | §103 | Final Rejection | 14d | Pending | Jul 29, 2025 |
| 19282184 | PROCESS OF PURIFICATION OF PROTEIN | Kashiv Biosciences, LLC | ROONEY, NORA MAUREEN | 1641 | §112DP | Non-Final OA | — | Pending | Jul 28, 2025 |
| 19244554 | METHODS TO MODIFY BEHAVIORS TO MITIGATE IMPACT OF PREDICTION INACCURACIES FOR LATER TIME WINDOWS IN AMD SYSTEMS | Insulet Corporation | GILLIGAN, CHRISTOPHER L | 3683 | §103 | Final Rejection | — | Pending | Jun 20, 2025 |
| 19220387 | SYSTEMS AND METHODS FOR DETERMINING ASSET IMPORTANCE IN SECURITY RISK MANAGEMENT | Bitsight Technologies, Inc. | MANIWANG, JOSEPH R | DP | Non-Final OA | — | Pending | May 28, 2025 | |
| 19211805 | ON-BODY INTERLOCK FOR DRUG DELIVERY DEVICE | Insulet Corporation | STIGELL, THEODORE J | 3783 | §103§112DP | Non-Final OA | — | Pending | May 19, 2025 |
| 19197571 | SYSTEMS AND METHODS FOR DATA STRUCTURE ANALYSIS | Gestalt Tech Corp. | SAMARA, HUSAM TURKI | 2161 | §103 | Final Rejection | 36d overdue | Pending | May 02, 2025 |
| 19196457 | IgE PROTEASES AND USES THEREOF | Seismic Therapeutic, Inc. | DESAI, ANAND U | 1655 | §102§103§112 | Non-Final OA | — | Pending | May 01, 2025 |
| 19180988 | EARLY MEAL DETECTION AND CALORIE INTAKE DETECTION | Insulet Corporation | NGUYEN, HIEP VAN | 3686 | §101§103 | Non-Final OA | — | Pending | Apr 16, 2025 |
| 19171119 | SYSTEM TO CREATE CELLULAR LYSIS AND DELIVER FLUIDS INTRATUMORALLY | Syncromune, Inc. | SHOULDERS, ANNIE LEE | §102§103 | Non-Final OA | — | Pending | Apr 04, 2025 | |
| 19087070 | POLY-DONOR CD4+ T CELLS EXPRESSING IL-10 AND USES THEREOF | Tr1X, Inc. | NGUYEN, QUANG | 1631 | §103§112Other | Non-Final OA | — | Pending | Mar 21, 2025 |
| 19079820 | IMAGE-GUIDED ROBOTIC SYSTEM WITH REMOTE GUIDANCE, IMAGE STEERING, MULTI-PLANE IMAGING, NEEDLE VISUALIZATION ENHANCEMENT, AND CONSTRAINED BACKDRIVING | Mendaera, Inc. | BRUTUS, JOEL F | 3797 | §103 | Final Rejection | 30d overdue | Pending | Mar 14, 2025 |
| 19073748 | SYSTEMS AND METHODS FOR CUSTOMIZING ONLINE GAMING | Magnetic Games AB | ADAMS, CARL | §102§103 | Non-Final OA | — | Pending | Mar 07, 2025 | |
| 19068816 | ION IDENTIFICATION USING ION MOBILITY SPECTROMETRY | Micromass UK Limited | LE, THANG XUAN | §102Other | Non-Final OA | — | Pending | Mar 03, 2025 | |
| 19047061 | METHODS AND SYSTEMS FOR ANALYZING IMAGES FOR PRECISION TISSUE MICROARRAY CONSTRUCTION | Noetik Inc. | CROCKETT, JOSHUA BRIGHAM | §103§112 | Non-Final OA | — | Pending | Feb 06, 2025 | |
| 19039593 | FABRICATION OF POLYCRYSTALLINE SILICON NITRIDE FIBERS | Bluehalo, LLC | DAIGLER, CHRISTOPHER PAUL | §101§103 | Non-Final OA | — | Pending | Jan 28, 2025 | |
| 19035537 | APPARATUS FOR GLYCEMIC CONTROL | Insulet Corporation | KOLOSOWSKI-GAGER, KATHERINE | 3687 | §101§103 | Final Rejection | 42d overdue | Pending | Jan 23, 2025 |
| 19022962 | METHOD AND SYSTEM FOR ASSET ROUTING | Lob.Com, Inc. | WALLACE, JOHN R | §103Other | Non-Final OA | — | Pending | Jan 15, 2025 | |
| 19022649 | METHOD FOR PREPARING METALLIC COBALT THIN FILM AND METHOD FOR PREPARING COBALT SILICIDE THIN FILM | BEIJING SUPERSTRING ACADEMY OF MEMORY TECHNOLOGY | TALBOT, BRIAN K | 1712 | §103§112 | Final Rejection | — | Pending | Jan 15, 2025 |
| 19013936 | SYSTEMS AND METHODS FOR UNDERGROUND STORAGE OF STORM AND OTHER WATER SOURCES | Underground Industries LLC | TOLEDO-DURAN, EDWIN J | §102§103§112Other | Non-Final OA | — | Pending | Jan 08, 2025 | |
| 19012213 | SYSTEM AND METHOD FOR TREATMENT OF MEDICAL CONDITIONS USING MULTIPLE BLOOD PRESSURE SENSORS | Aktiia SA | YOON, CHANEL J | 3791 | §101§103§112 | Non-Final OA | — | Pending | Jan 07, 2025 |
| 19004969 | LOGGING AND ANALYZING ROBOTIC PICKING DATA | Oxipital AI Inc. | NELESKI, ELIZABETH ROSE | 3658 | §103 | Final Rejection | 14d | Pending | Dec 30, 2024 |
| 18974588 | NINTEDANIB AND NINTEDANIB COMBINATION DRY POWDER COMPOSITIONS AND USES | Avalyn Pharma Inc. | ZHANG SPIERING, DONGXIU | §103§112DP | Non-Final OA | — | Pending | Dec 09, 2024 | |
| 18971800 | SOLID FORMS OF AN ULK INHIBITOR | Deciphera Pharmaceuticals, LLC | SEITZ, ANTHONY JOSEPH | §103§112 | Non-Final OA | — | Pending | Dec 06, 2024 | |
| 18870188 | SYSTEM AND METHODS FOR PREDICTING GLAUCOMA INCIDENCE AND PROGRESSION USING RETINAL PHOTOGRAPHS | Antinous Technology Company Limited | FUJITA, KATRINA R | §102§103 | Non-Final OA | — | Pending | Nov 27, 2024 | |
| 18958722 | COMPOSITE BUILDING MATERIALS AND METHODS OF MANUFACTURE | Rise Building Products LLC | CHOI, PETER Y | 1786 | §103 | Final Rejection | — | Pending | Nov 25, 2024 |
| 18952889 | NOVEL ANTI-PD-L1 ANTIBODIES | Wuxi Biologics Ireland Limited | ROONEY, NORA MAUREEN | §112Other | Non-Final OA | — | Pending | Nov 19, 2024 | |
| 18945759 | SYSTEMS AND METHODS FOR PATIENT TARGETED THERAPY DEVELOPMENT | Flagship Pioneering Innovations Vi, LLC | PAULS, JOHN A | 3683 | §101§103DP | Final Rejection | 23d overdue | Pending | Nov 13, 2024 |
| 18941833 | COSMETIC COMPOSITIONS | Eleblend LLC | PHAN, DOAN THI-THUC | §102§103§112 | Non-Final OA | — | Pending | Nov 08, 2024 | |
| 18941986 | 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Deuterx, LLC | WARD, PAUL V | DP | Non-Final OA | — | Pending | Nov 08, 2024 | |
| 18938818 | COMPACT LIQUID CHROMATOGRAPHY SYSTEM PROVIDING THERMAL MANAGEMENT AND DETECTION | Waters Technologies Corporation | SINGER, DAVID L | §103Other | Non-Final OA | — | Pending | Nov 06, 2024 | |
| 18936787 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS | Ensoma, Inc. | PAGUIO FRISING, MICHELLE F | §103§112DP | Non-Final OA | — | Pending | Nov 04, 2024 | |
| 18862402 | METHOD FOR SETTING UP AN ORTHOPAEDIC DEVICE | Ottobock SE & Co. Kgaa | WAGGLE, JR, LARRY E | §102§112 | Non-Final OA | — | Pending | Nov 01, 2024 | |
| 18932353 | MANUALLY OPERATED PUMP ASSEMBLY | Kickstart International, Inc. | PEKARSKAYA, LILYA | 3746 | §102§103 | Final Rejection | — | Pending | Oct 30, 2024 |
| 18860528 | PROLONGED AIR LEAK PERCEPTION | Texas Medical Center | MONTICELLO, WILLIAM THOMAS | 3682 | §101§102 | Non-Final OA | 35d | Pending | Oct 25, 2024 |
| 18925636 | WEARABLE SENSOR HAVING AN ADHESIVE, AND A MANUFACTURING METHOD | Occam Bci, Inc. | XU, JUSTIN | §103 | Non-Final OA | — | Pending | Oct 24, 2024 | |
| 18916566 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODIES AND METHODS OF USING THE SAME | Upstream Bio, Inc. | DUFFY, PATRICIA ANN | DP | Non-Final OA | — | Pending | Oct 15, 2024 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial74.5% of resolved applications prosecuted by Goodwin Procter LLP were allowed, across 12,326 applications in USPTO records.
3.51 office actions per allowed application on average.
402 pending office actions as of October 2026, for 192 clients, before 332 examiners in 112 art units.